The 24th Conference on Retroviruses and Opportunistic Infections (CROI 2017) was held in Seattle from 13-16 February 2017.
More than 4000 researchers and health workers (and a good inclusion of community activists) worked through more than 1000 studies presented at the meeting.
Luckily, CROI supports open access to the conference materials online, including comprehensive webcasts of all oral presentations – available immediately after each session.
The programme for the meeting and abstract books can be downloaded as PDF files.
The searchable abstracts database links directly to PDF files for most posters.
CROI is one of the leading scientific HIV meetings. But despite the last minute reversal of the proposed US travel restrictions, many delegates were suggesting that if similar entry restrictions are reimposed, then international medical conferences should perhaps not be held in the US and that CROI could be moved to Mexico or Canada.
This detracts nothing from the leading work by IAS-USA and US scientists. It is a way to refuse to normalise racist policies than exclude global inclusion in medical conferences.
And the exciting news: there will be much to report, especially in the following areas:
- New HIV treatments. Several studies present new data on new nukes (MK-8591 and GS-9131), NNRTIs (doravirine and elsulfavirine), integrase inhibitors (cabotegravir, bictegravir), and monoclonal antibodies (ibalizumab, PRO140 and UB-421).
- HIV and ageing. Especially the issue of neurocognitive performance.
- Reduced drug maintenance strategies. Using two or even one drug rather than three; including studies on dolutegravir monotherapy (which is no longer recommended) and dual therapy with lamivudine.
- HIV and children. Notably first results using dolutegravir in 2–6 year olds, and exposure data from crushed tablets; lopinavir super boosted with rifampicin-based TB co-treatment, and problems with starting this protease inhibitor at seven days of life. Several studies look at starting ART early in neonates.
- Treatment access. 90:90:90 updates, including the importance on including migrants in national targets, not doing so can be a barrier to population health.
- ART in pregnancy. Including adverse birth outcomes according to ART regimen.
- Anal cancer. Sceening, diagnosis and treatment.
- Coinfections – TB and HCV. New treatments for TB and looking at TB IRIS. New hepatitis C drugs including results in people with coinfection and cirrhosis and the impact on sexual transmission in gay men.
- Lifestyle-related changes. Smoking, diet and exercise.
- PrEP. A major focus for prevention – and including a rare case of infection despite good adherence.
- Advances in cure research. Including interventions in acute infection and stem sell transplantation.
- Health literacy, demographics and viral load outcomes. Subjects close to our heart…
Early HTB reports from CROI 2017 are already online
Dolutegravir monotherapy studies stopped due to integrase resistance: dual therapy studies continue
Disappointing news that the risk of drug resistance is sufficiently serious for several dolutegravir monotherapy studies to have stopped. Dual therapy with 3TC is still being studied.
- Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana
- No increase in adverse birth outcomes with maternal TDF/FTC in US study
Acute infection with wild-type HIV on PrEP with good drug levels
Rare case report of PrEP failure with complex details.
No evidence of accelerated brain ageing in HIV positive people on effective ART
Encouraging results from longitudinal imaging study.
NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV
Pre-clinical data on a compound that has had a low profile for the last decade.
Pharmacokinetics, safety and efficacy of dolutegravir in very young children
Important results on new formulation of dolutegravir for use in children aged 2 to 6 years old.
Dolutegravir exposure increases when fixed dose combination tablets are crushed
A new option looks possible for people who have difficulty swallowing pills.
New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study
Results at 48 weeks for compound with activity against first-generation NNRTI resistance.
Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor
Detailed results on this new integrase inhibitor that was featured in yesterday’s press conference.
Fit for purpose: antiretroviral treatment optimisation (Feb 2017)
Updated i-Base review on research approaches to using lower doses of some ARVs – produced to support think tank meetings at CROI.
Bictegravir vs dolutegravir: 24- and 48-week results from phase 2 study
Limited results from press conference – full study results to be updated after presentation tomorrow.
Seattle-lite: pre-conference workshops – watch online
Webcasts are already online from the pre-conference workshop and opening lectures – highly recommended.